Davita - Grayling Home Training is a medicare approved dialysis facility center in Grayling, Michigan and it has 0 dialysis stations. It is located in Crawford county at 125 E Michigan Ave, Grayling, MI, 49738. You can reach out to the office of Davita - Grayling Home Training at (989) 344-0805. This dialysis clinic is managed and/or owned by Davita. Davita - Grayling Home Training has the following ownership type - Profit. It was first certified by medicare in August, 2014. The medicare id for this facility is 232692 and it accepts patients under medicare ESRD program.
| Name | Davita - Grayling Home Training |
|---|---|
| Location | 125 E Michigan Ave, Grayling, Michigan |
| No. of Dialysis Stations | 0 |
| Medicare ID | 232692 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 125 E Michigan Ave, Grayling, Michigan, 49738 | |
| (989) 344-0805 | |
| Not Available |
News Archive
Gaining new insight to managing sodium balance and blood pressure, investigators at the University of Houston (UH) College of Pharmacy believe their work may identify future therapeutic targets to control hypertension.
A Cardiff University-led study has discovered that a protein provides protection against the effects of alcohol in the pancreas.
Not all brain cancers are the same but together they represent a deadly disease that has been difficult to identify and treat. Scientists at multiple institutions have found a new way of classifying brain cancers that could very well change how the illness is diagnosed and treated.
Bristol-Myers Squibb has announced the submission of a New Drug Application to the U.S. Food and Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic Hepatitis B.
CMC Biologics, a global leader in clinical and commercial development and contract manufacture of therapeutic proteins, announced today it has entered into an agreement with the PATH Malaria Vaccine Initiative (MVI) for process development and manufacture of specific monoclonal antibodies to test for their capacity to protect humans from malaria infection.
› Verified 3 days ago
| NPI Number | 1043552805 |
| Organization Name | Grayling Home Training |
| Doing Business As | Everglades Dialysis Llc |
| Address | 125 E Michigan Ave Grayling, Michigan, 49738 |
| Phone Number | (989) 344-0805 |
News Archive
Gaining new insight to managing sodium balance and blood pressure, investigators at the University of Houston (UH) College of Pharmacy believe their work may identify future therapeutic targets to control hypertension.
A Cardiff University-led study has discovered that a protein provides protection against the effects of alcohol in the pancreas.
Not all brain cancers are the same but together they represent a deadly disease that has been difficult to identify and treat. Scientists at multiple institutions have found a new way of classifying brain cancers that could very well change how the illness is diagnosed and treated.
Bristol-Myers Squibb has announced the submission of a New Drug Application to the U.S. Food and Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic Hepatitis B.
CMC Biologics, a global leader in clinical and commercial development and contract manufacture of therapeutic proteins, announced today it has entered into an agreement with the PATH Malaria Vaccine Initiative (MVI) for process development and manufacture of specific monoclonal antibodies to test for their capacity to protect humans from malaria infection.
› Verified 3 days ago
| Dialysis patients with Hemoglobin data | 3 |
News Archive
Gaining new insight to managing sodium balance and blood pressure, investigators at the University of Houston (UH) College of Pharmacy believe their work may identify future therapeutic targets to control hypertension.
A Cardiff University-led study has discovered that a protein provides protection against the effects of alcohol in the pancreas.
Not all brain cancers are the same but together they represent a deadly disease that has been difficult to identify and treat. Scientists at multiple institutions have found a new way of classifying brain cancers that could very well change how the illness is diagnosed and treated.
Bristol-Myers Squibb has announced the submission of a New Drug Application to the U.S. Food and Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic Hepatitis B.
CMC Biologics, a global leader in clinical and commercial development and contract manufacture of therapeutic proteins, announced today it has entered into an agreement with the PATH Malaria Vaccine Initiative (MVI) for process development and manufacture of specific monoclonal antibodies to test for their capacity to protect humans from malaria infection.
› Verified 3 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular peritoneal dialysis at the center | 8 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 53 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Gaining new insight to managing sodium balance and blood pressure, investigators at the University of Houston (UH) College of Pharmacy believe their work may identify future therapeutic targets to control hypertension.
A Cardiff University-led study has discovered that a protein provides protection against the effects of alcohol in the pancreas.
Not all brain cancers are the same but together they represent a deadly disease that has been difficult to identify and treat. Scientists at multiple institutions have found a new way of classifying brain cancers that could very well change how the illness is diagnosed and treated.
Bristol-Myers Squibb has announced the submission of a New Drug Application to the U.S. Food and Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic Hepatitis B.
CMC Biologics, a global leader in clinical and commercial development and contract manufacture of therapeutic proteins, announced today it has entered into an agreement with the PATH Malaria Vaccine Initiative (MVI) for process development and manufacture of specific monoclonal antibodies to test for their capacity to protect humans from malaria infection.
› Verified 3 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Davita - Grayling Home Training with elevated calcium levels.
| Patients with hypercalcemia | 11 |
| Hypercalcemia patient months | 87 |
| Patients with Serumphosphor | 12 |
| Patients with Serumphosphor less than 3.5 mg/dL | 7 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 24 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 38 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 18 |
| Patients with Serumphosphor greater than 7 mg/dL | 13 |
News Archive
Gaining new insight to managing sodium balance and blood pressure, investigators at the University of Houston (UH) College of Pharmacy believe their work may identify future therapeutic targets to control hypertension.
A Cardiff University-led study has discovered that a protein provides protection against the effects of alcohol in the pancreas.
Not all brain cancers are the same but together they represent a deadly disease that has been difficult to identify and treat. Scientists at multiple institutions have found a new way of classifying brain cancers that could very well change how the illness is diagnosed and treated.
Bristol-Myers Squibb has announced the submission of a New Drug Application to the U.S. Food and Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic Hepatitis B.
CMC Biologics, a global leader in clinical and commercial development and contract manufacture of therapeutic proteins, announced today it has entered into an agreement with the PATH Malaria Vaccine Initiative (MVI) for process development and manufacture of specific monoclonal antibodies to test for their capacity to protect humans from malaria infection.
› Verified 3 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 2 |
| Patient months included in arterial venous fistula and catheter summaries | 13 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer |
News Archive
Gaining new insight to managing sodium balance and blood pressure, investigators at the University of Houston (UH) College of Pharmacy believe their work may identify future therapeutic targets to control hypertension.
A Cardiff University-led study has discovered that a protein provides protection against the effects of alcohol in the pancreas.
Not all brain cancers are the same but together they represent a deadly disease that has been difficult to identify and treat. Scientists at multiple institutions have found a new way of classifying brain cancers that could very well change how the illness is diagnosed and treated.
Bristol-Myers Squibb has announced the submission of a New Drug Application to the U.S. Food and Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic Hepatitis B.
CMC Biologics, a global leader in clinical and commercial development and contract manufacture of therapeutic proteins, announced today it has entered into an agreement with the PATH Malaria Vaccine Initiative (MVI) for process development and manufacture of specific monoclonal antibodies to test for their capacity to protect humans from malaria infection.
› Verified 3 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 10 |
| Hospitalization Rate in facility | 271 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 846.7 |
| Hospitalization Rate: Lower Confidence Limit | 94.9 |
News Archive
Gaining new insight to managing sodium balance and blood pressure, investigators at the University of Houston (UH) College of Pharmacy believe their work may identify future therapeutic targets to control hypertension.
A Cardiff University-led study has discovered that a protein provides protection against the effects of alcohol in the pancreas.
Not all brain cancers are the same but together they represent a deadly disease that has been difficult to identify and treat. Scientists at multiple institutions have found a new way of classifying brain cancers that could very well change how the illness is diagnosed and treated.
Bristol-Myers Squibb has announced the submission of a New Drug Application to the U.S. Food and Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic Hepatitis B.
CMC Biologics, a global leader in clinical and commercial development and contract manufacture of therapeutic proteins, announced today it has entered into an agreement with the PATH Malaria Vaccine Initiative (MVI) for process development and manufacture of specific monoclonal antibodies to test for their capacity to protect humans from malaria infection.
› Verified 3 days ago
The rate of readmission show you whether patients who were being treated regularly at Davita - Grayling Home Training were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 30.2 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 59.2 |
| Readmission Rate: Lower Confidence Limit | 10.9 |
News Archive
Gaining new insight to managing sodium balance and blood pressure, investigators at the University of Houston (UH) College of Pharmacy believe their work may identify future therapeutic targets to control hypertension.
A Cardiff University-led study has discovered that a protein provides protection against the effects of alcohol in the pancreas.
Not all brain cancers are the same but together they represent a deadly disease that has been difficult to identify and treat. Scientists at multiple institutions have found a new way of classifying brain cancers that could very well change how the illness is diagnosed and treated.
Bristol-Myers Squibb has announced the submission of a New Drug Application to the U.S. Food and Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic Hepatitis B.
CMC Biologics, a global leader in clinical and commercial development and contract manufacture of therapeutic proteins, announced today it has entered into an agreement with the PATH Malaria Vaccine Initiative (MVI) for process development and manufacture of specific monoclonal antibodies to test for their capacity to protect humans from malaria infection.
› Verified 3 days ago